Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours. by Lissoni, P. et al.
Br. J. Cancer (1989), 60, 616-617 The Macmillan Press Ltd., 1989
SHORT COMMUNICATION
Serum levels of soluble interleukin-2 receptors and their relation to
lymphocyte subpopulations in patients with metastatic solid tumours
P. Lissoni', S. Barnil, R. Rescaldani2, F. Rovelli' & G. Tancini'
'Divisione di Radioterapia Oncologica and 2Laboratorio di Microbiologia, Hospital ofMonza, 20052, Monza, Milan, Italy.
It has been demonstrated that both activated normal and
transformed lymphocytes can produce not only a cell surface-
linked, but also a soluble form of interleukin-2 (IL-2) recep-
tor, which can be detected in the blood (Rubin et al., 1985).
High serum levels of soluble interleukin-2 receptors (sIL-2R)
have been observed in patients suffering from malignant
lymphomas, either in Hodgkin's disease (Pizzolo et al., 1987)
or in non-Hodgkin's lymphomas (Wagner et al., 1987), and
in those affected by leukaemia (Chilosi et al., 1986).
Moreover, recent studies have shown that elevated concentra-
tions of sIL-2R can also be found in patients with
disseminated solid tumours (Rovelli et al., 1988).
Because of their correlation to the extension of disease,
sIL-2R have been considered as tumour markers in emolym-
phopoietic neoplasias. On the contrary, the mechanisms
responsible for the enhanced release of sIL-2R and their
possible clinical significance in patients with solid tumours
have not yet been clarified. Even if it has been demonstrated
that sIL-2R can bind IL-2 (Rubin et al., 1986), their affinity
is low, and it is therefore improbable that an increase in
sIL-2R blood levels may really cause a diminished
availability of IL-2 and induce an immunosuppressive status.
Thus, at present it has still to be established if sIL-2R may
be considered or not as a marker of host biological response
in solid neoplasms.
None of the single immune parameters investigated up to
now has appeared to be exhaustive of the immune status in
cancer patients. Nevertheless, a reduced or inverted T helper/
suppressor ratio can be often observed in metastatic cancer
patients (Dillman et al., 1984), and this finding has been
interpreted as an index of immunosuppression.
In order to analyse which is the immune significance of
sIL-2R concentrations in solid neoplasms, in this preliminary
study we have investigated the relation between sIL-2R and
lymphocyte subpopulations, the importance of which is bet-
ter defined, in a group of patients with metastatic solid
tumours. The study was carried out on 32 patients of both
sexes, with a median age of 57 years (range 36-72), suffering
from metastatic solid neoplasms. Patients treated with
chemotherapy were studied at least 30 days after the last
administration of cytotoxic drugs. Moreover, to exclude the
possible interference of illnesses other than cancer, patients
with concomitant infectious diseases were not included in this
investigation. Finally, no patient was under therapy with
steroids or opioid substances at the time during which the
study was carried out. Tumour types were: lung cancer, 12;
breast cancer, 9; colorectal carcinoma, 5; gastric cancer, 6. As
controls, a first group of 58 age-matched healthy subjects,
and a second group of 24 patients with locally limited solid
tumours (breast cancer, 9; lung cancer, 6; colorectal cancer,
5; gastric cancer, 4) were included in the study.
To evaluate sIL-2R serum levels and lymphocyte sub-
populations, venous blood samples were drawn during the
morning. sIL-2R were measured with an enzyme immunoas-
say, using commercial kits (T Cell Sciences, Cambridge,
MA), developed using two monoclonal antibodies directed
against non-overlapping epitopes on the human IL-2R. Nor-
mal values obtained in our laboratory were less than
480 U ml-'. The sensitivity of the assay was 50 U ml-'.
Intra-assay and interassay coefficients of variation were 4%
and 11%, respectively. Recovery was 97%. B lymphocytes
(B), T helper/inducer (CD4), T suppressor/cytotoxic (CD8)
and total T lymphocytes (CD3) were measured using a flow
cytometric analysis, by using monoclonal antibodies supplied
by Ortho Diagnostics (Raritan, NJ). The normal value of
CD4/CD8 ratio in our laboratory was > 1.2. Results were
reported as mean ± s.e., and analysed by Student's t test and
coefficient of correlation, as appropriate. The values found in
the normal subjects and in patients are reported in Table I.
High serum levels of sIL-2R were found in 24/32 (75%)
metastatic patients, and in only 4/24 (16.6%) non-metastatic
cancer patients. Mean values of sIL-2R were significantly
higher in metastatic patients than those seen either in non-
metastatic cancer patients (P<0.001) or in healthy controls
(P<0.001). A reduced or inverted CD4/CD8 ratio was found
in 17/32 (53%) metastatic cancer patients, and in only 3/24
(12.5%) non-metastatic patients. CD4/CD8 mean value was
significantly lower in metastatic patients than in those with-
out metastases (P<0.005). Within the metastatic group, sIL-
2R were higher in patients with a normal CD4/CD8 ratio
than in those with a low ratio, but this difference was not
significant. Moreover, no significant correlation was seen
between leukocyte number and sIL-2R. Finally, none of the
lymphocytes subpopulations was significantly correlated to
sIL-2R serum levels.
These results confirm that immune dysfunctions can often
be observed in patients with metastatic solid neoplasms, as
suggested by the reduced CD4/CD8 ratio in a great number
of cases. Moreover, this study demonstrates that metastatic
solid tumours are also associated with increased levels of
sIL-2R. The results of this study, however, do not allow us
to affirm that the increased levels of sIL-2R can be also
considered as a marker of immune dysfunction, because of
their lack of correlation to CD4/CD8 ratio, which decrease
represents a sign of immunosuppression.
The mechanisms responsible for the increased release of
sIL-2R in patients with disseminated solid tumours are still
obscure; however, it could be due to unknown factors pro-
duced by cancer cells themselves, capable of affecting the
normal expression of IL-2R on cell surface. In any case,
further studies, by correlating sIL-2R with other important
immune parameters, particularly the percentage of TAC-
positive cells, will be required to understand which factors
regulate sIL-2R release and to explain their possible
significance in relation to host immune status in patients with
advanced solid neoplasms.
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Table I Soluble interleukin-2 receptors (sIL-2R) serum levels (mean ± s.e.) and lymphocyte subpopulations (mean ± s.e.) in cancer
patients and healthy subjects
Cases n sIL-2R (Uml-') WBCO La B CD3 CD4 CD8 CD4/CD8
(n x 103mmr) (%) (% (% (%) (%
Healthy subjects (HS) 58 278 21 6.8 0.9 26 3 17 1 75 3 46 3 26 2 1.9 0.2
Non-metastatic patients (NMP) 24 363 ± 24 6.4 ± 2.2 22 ± 4 16 ± 1 73 + 3 43 ± 4 28 ± 3 1.7 ± 0.1
Metastatic patients (MP) 32 1026 143b 10.9 ± 1.7 19 ± 2 18 ± 2 72 2 37 ± 2 34+ 1 1.1 ± 0.1
NormalCD4/CD8 15 1137±254b 8.7±0.9 24±3 21 3 72±2 43 1 30 1 1.5±0.1
LowCD4/CD8 17 929 158b 12.8±3.1 16±2 15±2 72±3 32±2e 39+2f 0.8±0.05d
aWBC, white blood cells; L, lymphocytes. bP<O.001 vs HS and NMP; CP<0.005 vs HS and NMP; dP<0.001 vs all other groups; CP<0.001 vs all other groups; 'P<0.005 vs all other groups.
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